Ridaforolimus: all 33 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)TerminatedNCT01431534Phase 1Results posted
• Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)CompletedNCT01380184Phase 1Results posted
• A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)TerminatedNCT01243762Phase 1Results posted
• Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck CancerTerminatedNCT01212627Phase 1Results posted
• Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT01169532Phase 1Results posted
• A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)CompletedNCT00874731Phase 1Results posted
• Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)TerminatedNCT00836927Phase 2Results posted
• Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)CompletedNCT01431547Phase 1
• Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue SarcomaWithdrawnNCT01296659Phase 1
• Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and SolidsCompletedNCT01256268Phase 1
• A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)CompletedNCT01234857Phase 2
• The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)CompletedNCT01220570Phase 1
• Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)CompletedNCT01071304Phase 1
• Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)CompletedNCT01043887Phase 1
• Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)CompletedNCT01010672Phase 2
• Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)CompletedNCT00781846Phase 1
• Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)CompletedNCT00777959Phase 2
• Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial CancerCompletedNCT00770185Phase 2
• Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)CompletedNCT00739830Phase 2
• Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)CompletedNCT00736970Phase 2
• A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)CompletedNCT00730379Phase 1
• A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)CompletedNCT00704054Phase 1
• Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)CompletedNCT00694083Phase 1
• Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)CompletedNCT00538239Phase 3
• Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)CompletedNCT00288431Phase 1
• AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)CompletedNCT00122343Phase 2
• Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)CompletedNCT00112372Phase 1
• Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)CompletedNCT00110188Phase 2
• Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)CompletedNCT00093080Phase 2
• Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)CompletedNCT00087451Phase 1
• Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)CompletedNCT00086125Phase 2
• Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)CompletedNCT00060645Phase 1
• Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)CompletedNCT00060632Phase 1

← Ridaforolimus overview